Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03245892 · ClinicalTrials.gov registry record · Phase 1
A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer
A Phase 1 study of Primary Peritoneal Cancer and Fallopian Tube, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT03245892 is a Phase 1 study of Primary Peritoneal Cancer and Fallopian Tube that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 27 participants, below the 151-participant average among 27 other Primary Peritoneal Cancer trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03245892, a Phase 1 study of Primary Peritoneal Cancer and Fallopian Tube, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out what effects, good or bad, the addition of nivolumab or the combination of nivolumab plus ipilimumab to typical chemotherapy has on the treatment of advanced high-grade serous cancers of ovarian, fallopian tube, or primary peritoneal origin. The typical chemotherapy treatment is Carboplatin and Paclitaxel.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- PROCEDURE Cytoreductive surgery
- DRUG Carboplatin and Paclitaxel
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2017-08-04 |
| Est. Completion | 2025-12-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03245892
The ClinicalTrials.gov registry entry for NCT03245892 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 151-participant average among 27 other Primary Peritoneal Cancer trials with a reported enrollment target (82% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Primary Peritoneal Cancer appearing as the primary indexed condition, and to 4 interventions - of which Nivolumab is the first listed.
NCT03245892 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03245892 about?
NCT03245892 is a clinical study titled "A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer". The purpose of this study is to find out what effects, good or bad, the addition of nivolumab or the combination of nivolumab plus ipilimumab to typical chemotherapy has on the treatment of advanced high-grade serous cancers of ovarian, fallopian tube, or primary peritoneal origin. The typical chemo...
What is the current status of trial NCT03245892?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2017-08-04. Estimated completion is 2025-12-04.
What conditions does trial NCT03245892 study?
This clinical trial studies the following conditions: Primary Peritoneal Cancer, Fallopian Tube, High Grade Serous Ovarian.
What interventions are being tested in trial NCT03245892?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Cytoreductive surgery (PROCEDURE), Carboplatin and Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT03245892?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03245892 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Peritoneal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 1
-
Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
RECRUITING · Phase 1
-
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
RECRUITING · Phase 1
-
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.